```html

Gynecological Cancer (Ovarian & Endometrial) – A Complete Patient Guide

Overview

Gynecological cancers are malignancies that arise from a woman’s reproductive organs. The two most common types are ovarian cancer and endometrial (uterine) cancer. Together they account for roughly 15% of all cancers diagnosed in women in the United States.

• Ovarian cancer: ~21,750 new cases & 13,940 deaths in 2024 (American Cancer Society).
• Endometrial cancer: ~66,200 new cases & 12,800 deaths in 2024 (CDC).

Both typically affect women over age 50, but they can occur at any age, including in younger women with hereditary cancer syndromes (e.g., BRCA1/2, Lynch syndrome). Racial and ethnic differences exist: African‑American women have higher mortality from ovarian cancer, while endometrial cancer is more common in White women but has a higher death rate among Black women.<sup>1</sup>

Symptoms

Early gynecologic cancers often produce vague or no symptoms, which is why routine health checks are essential. Below is a comprehensive list of signs reported by patients and clinicians.

Ovarian Cancer

• Abdominal bloating or swelling – persistent feeling of fullness even after a small meal.
• Pelvic or abdominal pain – may be dull, intermittent, or sharp.
• Changes in bowel habits – constipation, diarrhea, or feeling of incomplete evacuation.
• Urginary symptoms – urgency, frequency, or difficulty emptying the bladder.
• Unexplained weight loss or gain – despite unchanged diet or activity.
• Feeling of heaviness in the pelvis or a sensation of something “pressing” on the lower abdomen.
• Menstrual changes – especially post‑menopausal bleeding (rare but possible).

Endometrial (Uterine) Cancer

• Abnormal uterine bleeding – spotting between periods, heavy periods, or post‑menopausal bleeding.
• Pelvic pain or pressure – may be constant or worsen during intercourse.
• Unexplained weight loss or fatigue.
• Discharge – watery, brown, or blood‑stained discharge not related to menstruation.
• Changes in bowel or bladder habits – similar to ovarian symptoms, due to tumor proximity.

Because many of these symptoms overlap with benign conditions (e.g., fibroids, IBS), any persistent change lasting more than 2–4 weeks should prompt a medical evaluation.

Causes and Risk Factors

Both cancers arise from genetic mutations that cause normal cells to grow uncontrollably. While the exact trigger is often unknown, many modifiable and non‑modifiable risk factors have been identified.

Ovarian Cancer

• Age – risk rises sharply after age 50.
• Genetic mutations – BRCA1/2, RAD51C/D, and Lynch syndrome dramatically increase risk (up to 20‑30% lifetime risk).<sup>2</sup>
• Family history – first‑degree relatives with ovarian or breast cancer.
• Reproductive history – never having been pregnant, early menarche (<12 y), late menopause (>55 y), and infertility.
• Hormonal factors – hormone replacement therapy (especially estrogen‑only) for >5 years.
• Obesity – adipose tissue produces estrogen, which may stimulate ovarian epithelium.
• Endometriosis – chronic inflammation may predispose to certain ovarian subtypes.

Endometrial Cancer

• Age – median diagnosis at 62 y.
• Obesity – BMI ≥ 30 triples the risk; excess estrogen from fat tissue drives endometrial proliferation.<sup>3</sup>
• Hormone exposure – unopposed estrogen (e.g., estrogen‑only HRT, early menarche, late menopause).
• Polycystic ovary syndrome (PCOS) – chronic anovulation leads to prolonged estrogen exposure.
• Diabetes & hypertension – metabolic syndrome components are independent risk factors.
• Genetics – Lynch syndrome confers a 40‑60% lifetime risk; BRCA mutations also increase risk modestly.
• Nulliparity or never having carried a pregnancy to term.

Diagnosis

When cancer is suspected, a structured diagnostic pathway is employed to confirm the disease, determine stage, and guide treatment.

Initial Evaluation

• Medical history & physical exam – focus on pelvic exam, symptom chronology, and family cancer history.
• Transvaginal ultrasound (TVUS) – first‑line imaging; identifies ovarian masses and endometrial thickness.
• Pap smear & HPV testing – primarily for cervical cancer screening but may reveal abnormal cells prompting further work‑up.

Laboratory Tests

• CA‑125 – a blood tumor marker elevated in ~80% of advanced ovarian cancers; used for monitoring rather than screening.
• HE4 – another ovarian cancer marker; combined with CA‑125 in the ROMA algorithm to improve diagnostic accuracy.
• Endometrial biopsy – office‑based pipelle sampling or hysteroscopic biopsy to obtain tissue for pathology.
• Genetic testing – germline testing for BRCA1/2, Lynch syndrome, especially when family history is suggestive.

Imaging for Staging

• CT scan of abdomen & pelvis – assesses spread to lymph nodes, liver, or peritoneum.
• MRI – excellent for evaluating myometrial invasion in endometrial cancer.
• PET‑CT – functional imaging useful in selected ovarian cancer cases to detect metastases.
• Laparoscopy – minimally invasive surgery that allows direct visualization and biopsy, often the definitive diagnostic step for ovarian cancer.

Staging Systems

Both cancers use the International Federation of Gynecology and Obstetrics (FIGO) staging, ranging from Stage I (confined to the ovary or uterus) to Stage IV (distant metastasis). Accurate staging is critical for treatment planning.

Treatment Options

Treatment is individualized based on cancer type, stage, patient health, and personal preferences. A multimodal approach—combining surgery, systemic therapy, and radiation—offers the best outcomes for most patients.

Ovarian Cancer

• Primary cytoreductive (debulking) surgery – removal of as much tumor as possible; may involve hysterectomy, bilateral salpingo‑oophorectomy, omentectomy, and removal of affected lymph nodes.
• Adjuvant chemotherapy – standard regimen: carboplatin + paclitaxel every 3 weeks for 6 cycles. Intraperitoneal (IP) chemotherapy may be used in select Stage III cases.
• Targeted therapy –
  • PARP inhibitors (olaparib, niraparib, rucaparib) for BRCA‑mutated or homologous recombination‑deficient tumors.
  • Bevacizumab (anti‑VEGF) added to chemotherapy for advanced disease.
• Maintenance therapy – PARP inhibitors or bevacizumab continued after chemotherapy to prolong remission.
• Clinical trials – immunotherapy (PD‑1/PD‑L1 inhibitors) and novel antibody–drug conjugates are under investigation.

Endometrial Cancer

• Surgical staging – total hysterectomy with bilateral salpingo‑oophorectomy; often accompanied by sentinel lymph node mapping.
• Radiation therapy –
  • External beam radiation (EBRT) to pelvis.
  • Vaginal brachytherapy for high‑risk but node‑negative disease.
• Progestin therapy – high‑dose oral medroxyprogesterone acetate or levonorgestrel IUD for hormone‑sensitive, early‑stage disease, especially in women desiring fertility preservation.
• Systemic chemotherapy – carboplatin + paclitaxel for Stage III–IV or recurrent disease.
• Targeted agents – pembrolizumab (PD‑1 inhibitor) with lenvatinib for advanced or recurrent, microsatellite‑stable tumors; trastuzumab for HER2‑positive serous carcinoma.

Lifestyle & Supportive Measures

• Nutrition counseling – high‑protein, low‑sugar diet supports healing and maintains weight.
• Physical activity – moderate exercise (e.g., walking 150 min/week) improves fatigue and quality of life.
• Pain management – NSAIDs, neuropathic agents, or referral to a pain specialist.
• Psychosocial support – counseling, support groups, and survivorship programs.

Living with Gynecological Cancer

Beyond medical treatment, day‑to‑day management can make a huge difference in wellbeing.

Managing Side Effects

• Fatigue – schedule rest periods, prioritize tasks, consider light stretching or yoga.
• Nausea – eat small, bland meals; use prescribed anti‑emetics (e.g., ondansetron) before chemotherapy.
• Menopausal symptoms (from oophorectomy or hormonal therapy) – lubricants for vaginal dryness, non‑hormonal hot‑flash remedies, discuss risks of estrogen replacement with your oncologist.
• Lymphedema – if lymph nodes removed, wear compression garments and perform gentle lymphatic drainage exercises.

Follow‑up Care

Regular surveillance is essential:

• Physical exam and pelvic exam every 3–6 months for the first 2 years, then semi‑annually.
• CA‑125 monitoring (ovarian) or imaging as directed by your oncologist.
• Annual bone density testing if on long‑term aromatase inhibitors or other bone‑weakening meds.

Fertility & Family Planning

If you wish to preserve fertility, discuss options before definitive surgery:

• Egg or embryo freezing.
• Ovarian tissue cryopreservation (experimental).
• Use of a levonorgestrel IUD for early‑stage endometrial cancer.

Emotional Health

Living with cancer can trigger anxiety, depression, or grief. Resources include:

• Referral to a mental‑health professional experienced in oncology.
• Patient‑led support groups (e.g., Gynecologic Cancer Alliance, CancerCare).
• Mind‑body programs – meditation, guided imagery, or acupuncture for symptom relief.

Prevention

While not all cases are preventable, risk reduction strategies are well documented.

• Maintain a healthy weight – aim for BMI < 25; weight loss of 5‑10% can lower endometrial risk.
• Physical activity – at least 150 min of moderate aerobic exercise per week.
• Reproductive choices – pregnancy and breastfeeding appear protective; discuss family planning with a provider.
• Contraceptive use – combined oral contraceptives reduce ovarian cancer risk by up to 50% when used for ≥5 years.<sup>4</sup>
• Limit hormone therapy – use the lowest effective dose for the shortest time; prefer combined estrogen‑progestin over estrogen‑only when possible.
• Genetic counseling & testing – for women with strong family histories; risk‑reducing salpingo‑oophorectomy is recommended for BRCA carriers after childbearing.
• Screening for high‑risk individuals – transvaginal ultrasound and CA‑125 every 6‑12 months for BRCA or Lynch mutation carriers (clinical guidelines, NCCN).

Complications

If left untreated or inadequately managed, gynecologic cancers can lead to serious health problems.

• Ascites – fluid accumulation in the abdomen causing distension and shortness of breath (common in advanced ovarian cancer).
• Bowel obstruction – tumor infiltration or adhesions can block the intestines, requiring emergency surgery.
• Deep vein thrombosis (DVT) & pulmonary embolism – malignancy induces a hypercoagulable state.
• Malnutrition – due to appetite loss, nausea, or metabolic demands of the tumor.
• Secondary cancers – prior radiation or certain chemotherapies increase the risk of leukemia or other malignancies.
• Infertility – surgery or chemotherapy can damage ovarian reserve; discuss fertility preservation early.
• Psychological distress – chronic anxiety, depression, and post‑traumatic stress disorder are reported in up to 30% of survivors.

When to Seek Emergency Care

References

1. American Cancer Society. Gynecologic Cancers Fact Sheet. 2024. cancer.org.
2. National Comprehensive Cancer Network (NCCN). Guidelines for Ovarian Cancer. Version 2.2024.
3. World Health Organization. Obesity and Cancer Fact Sheet. 2023.
4. Centers for Disease Control and Prevention. Oral Contraceptives and Cancer Prevention. Updated 2023.

```